{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:07:15Z","timestamp":1763035635072},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":6549,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2002,2]]},"DOI":"10.1093\/annonc\/mdf038","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T18:59:57Z","timestamp":1027709997000},"page":"251-257","source":"Crossref","is-referenced-by-count":36,"title":["Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer"],"prefix":"10.1016","volume":"13","author":[{"given":"A.","family":"du Bois","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Meier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.J.","family":"L\u00fcck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Emons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Moebus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Bauknecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Olbricht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Jackisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdf038_bb0010","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin\u2013cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results","volume":"92","author":"Piccart","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdf038_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"issue":"Abstr 1374","key":"10.1093\/annonc\/mdf038_bb0020","first-page":"18","article-title":"Cisplatin\/paclitaxel vs carboplatin\/paclitaxel in ovarian cancer: Update of an AGO trial","volume":"356a","author":"du Bois","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Abstr 1373","key":"10.1093\/annonc\/mdf038_bb0025","first-page":"18","article-title":"Randomized phase III study of cisplatin (CIS)\/paclitaxel (PAC) versus carboplatin (CARBO)\/PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 158)","volume":"356a","author":"Ozols","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf038_bb0030","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2000.18.17.3084","article-title":"Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer","volume":"18","author":"Neijt","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf038_bb0035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0923-7534(20)31491-5","article-title":"Advanced epithelial ovarian cancer: 1998 consensus statements","volume":"10","author":"Berek","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf038_bb0040","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.1992.10.4.513","article-title":"Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population","volume":"10","author":"Markman","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf038_bb0045","first-page":"232","article-title":"High-dose versus low-dose cisplatin chemotherapy plus treosulfan in epithelial ovarian carcinoma FIGO II\u2013IV: results of a prospective randomized trial","volume":"23","author":"Merkle","year":"2000","journal-title":"Onkologie"},{"issue":"Abstr 832","key":"10.1093\/annonc\/mdf038_bb0050","first-page":"12","article-title":"PT vs PC (Cis-platinum\/treosulfan vs cis-platinum\/cyclophosphamide) in advanced ovarian carcinoma: a phase III study","volume":"261a","author":"Breitbach","year":"1993","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl 3","key":"10.1093\/annonc\/mdf038_bb0055","first-page":"89","volume":"14","author":"Hoffmann","year":"1991","journal-title":"Treosulfan in the treatment of ovarian carcinoma Onkologie"},{"key":"10.1093\/annonc\/mdf038_bb0060","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1055\/s-2007-1023097","article-title":"Treosulfan als effiziente second-line-therapie beim ovarialkarzinom","volume":"57","author":"Gropp","year":"1997","journal-title":"Geburtsh u Frauenheilkd"},{"key":"10.1093\/annonc\/mdf038_bb0065","first-page":"100","article-title":"Oral treosulfan as second-line treatment in platinum-resistant ovarian cancer: a phase II study","volume":"69","author":"Keldsen","year":"1998","journal-title":"The Danish Ovarian Cancer Study Group. Gynecol Oncol"},{"key":"10.1093\/annonc\/mdf038_bb0070","first-page":"374","article-title":"Chemotherapie des fortgeschrittenen ovarialkarzinoms","volume":"8","author":"K\u00fchnle","year":"1985","journal-title":"Onkologie"},{"key":"10.1093\/annonc\/mdf038_bb0075","first-page":"195","article-title":"Treosulfan als second-line-therapie beim fortgeschrittenen ovarialkarzinom","volume":"250","author":"Kramer","year":"1991","journal-title":"Arch Gynecol Obstet"},{"key":"10.1093\/annonc\/mdf038_bb0080","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00000421-199204000-00006","article-title":"A phase II trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group study","volume":"15","author":"Miller","year":"1992","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdf038_bb0085","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.1989.7.1.115","article-title":"Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer","volume":"7","author":"Kavanagh","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf038_bb0090","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/00003081-199309000-00025","article-title":"Effects of gonadotropin-releasing hormone analogues on ovarian epithelial tumors","volume":"36","author":"Adelson","year":"1993","journal-title":"Clin Obstet Gynecol"},{"key":"10.1093\/annonc\/mdf038_bb0095","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/0002-9378(89)90669-8","article-title":"Treatment of advanced refractory ovarian carcinoma with a gonadotropin-releasing hormone analogue","volume":"161","author":"Bruckner","year":"1989","journal-title":"Am J Obstet Gynecol"},{"key":"10.1093\/annonc\/mdf038_bb0100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1525-1438.1996.06010015.x","article-title":"Combination therapy with leuprolide acetate and tamoxifen in refractory ovarian cancer","volume":"6","author":"Lopez","year":"1996","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdf038_bb0105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1525-1438.1998.09828.x","article-title":"Tamoxifen in relapsed ovarian cancer: a systematic review","volume":"8","author":"Williams","year":"1998","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdf038_bb0110","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-79-4-604","article-title":"Creatinine clearance: bedside estimate","volume":"79","author":"Jeliffe","year":"1973","journal-title":"Ann Intern Med"},{"key":"10.1093\/annonc\/mdf038_bb0115","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf038_bb0120","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1200\/JCO.1998.16.6.2233","article-title":"Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study","volume":"16","author":"Hoskins","year":"1998","journal-title":"J Clin Oncol"},{"issue":"Abstr 1504","key":"10.1093\/annonc\/mdf038_bb0125","first-page":"19","article-title":"Interim analysis of a phase III randomized trial of doxil\/caelyx (D) versus topotecan (T) in the treatment of patients with relapsed ovarian cancer","volume":"380a","author":"Gordon","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf038_bb0130","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1006\/gyno.1998.5237","article-title":"Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and \u2010resistant ovarian cancer","volume":"72","author":"Bolis","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdf038_bb0135","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/030089169908500401","article-title":"A phase I\u2013II trial of high-dose ifosfamide in patients with ovarian cancer refractory or resistant to platinum and\/or paclitaxel-containing chemotherapy","volume":"85","author":"Scarfone","year":"1999","journal-title":"Tumori"},{"key":"10.1093\/annonc\/mdf038_bb0140","first-page":"275","article-title":"Altretamine (Hexalen) an effective salvage chemotherapy after paclitaxel (Taxol) in women with recurrent platinum resistant ovarian cancer","volume":"14","author":"Schink","year":"1995","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Abstr 1603","key":"10.1093\/annonc\/mdf038_bb0145","first-page":"19","article-title":"Gemcitabine in platinum-paclitaxel resistant ovarian carcinoma","volume":"405a","author":"Coenen","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl 11","key":"10.1093\/annonc\/mdf038_bb0150","first-page":"38","article-title":"Pegylated liposomal doxorubicin: antitumor activity in epithelial ovarian cancer or cancer of peritoneal origin","volume":"11","author":"Muggia","year":"1997","journal-title":"Oncology"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419628097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419628097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/13\/2\/251\/19479724\/251.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T02:29:23Z","timestamp":1582165763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419628097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["S0923753419628097"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdf038","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2002,2]]}}}